Please check your internet connection and try again.
# Urimax (Tamsulosin)
## Overview
Tamsulosin is a selective α1-adrenoceptor antagonist that preferentially binds to α1A receptors in the prostate and bladder neck, causing relaxation of smooth muscle. This reduces resistance to urinary outflow.
## Primary Indications
* Management of signs and symptoms of benign prostatic hyperplasia (BPH).
* Off-label: Medical expulsive therapy for ureteral calculi (distal stones).
## Adult Dosing
* **BPH:** 0.4 mg orally once daily, taken 30 minutes after the same meal each day.
* **Max Dosage:** 0.8 mg daily (if inadequate response to 0.4 mg after 2–4 weeks).
## Pediatric Dosing
* **Safety/Efficacy:** Not established. Use is generally avoided in pediatric patients due to lack of evidence and potential for significant cardiovascular side effects (orthostatic hypotension).
## Dose Adjustments
* **Renal Impairment:** No dose adjustment required for mild to severe impairment.
* **Hepatic Impairment:** No dose adjustment required for mild to moderate impairment; use caution in severe hepatic impairment.
* **CYP3A4/2D6 Inhibitors:** Avoid or use with extreme caution if co-administered with strong inhibitors (e.g., ketoconazole, ritonavir).
## Contraindications
* Hypersensitivity to tamsulosin or any component of the formulation.
* History of angioedema.
## Adverse Effects
* **Common:** Dizziness, headache, abnormal ejaculation (retrograde ejaculation), rhinitis, orthostatic hypotension.
* **Serious:** Intraoperative floppy iris syndrome (IFIS) during cataract surgery, syncope, priapism, severe allergic reactions.
## Key Drug Interactions
* **PDE-5 Inhibitors (e.g., sildenafil, tadalafil):** Increases risk of additive hypotensive effects.
* **Strong CYP3A4 inhibitors:** Significantly increase serum concentrations of tamsulosin.
* **Other Alpha-Blockers/Antihypertensives:** Potential for additive blood pressure lowering.
## Monitoring
* Monitor blood pressure periodically, especially upon initiation or dosage escalation.
* Monitor for symptoms of orthostasis.
* Determine if patient is scheduled for cataract surgery; notify the ophthalmologist of current/prior tamsulosin use.
## Clinical Pearls
* **Administration:** Must be swallowed whole. Do not crush, chew, or open the capsule to ensure controlled release.
* **Timing:** Taking the medication at the same time relative to a meal is critical to achieve consistent bioavailability.
* **First-Dose Phenomenon:** Patients may experience dizziness/syncope. Advise patients to rise slowly from a sitting or lying position.
* **IFIS:** The association with cataract surgery is independent of the timing of the last dose; even after discontinuation, the risk remains for patients who have previously taken alpha-blockers.
***
*Disclaimer: This information is for educational purposes only. Drug information is subject to change based on evolving clinical guidelines and regional regulations. Always verify current prescribing information, local clinical protocols, and patient-specific factors with verified medical resources before prescribing or administering medication.*
